BioCryst Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 4 trials

Phase 2 / 3 2 trials

TrialDrugs studiedStatusPrimary completion
A Long Term Safety Study of BCX7353 in Hereditary AngioedemaNCT03472040BCX7353Completed2022-04-27Actual
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksNCT02303626BCX4161Completed2016-01Actual

Phase 2 5 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Pharmacokinetics: Cmax Measure: Pharmacokinetics: AUC0-tau Measure: Pharmacokinetics: CL/F. After: Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Berotralstat Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6) of Berotralstat Measure: Concentration at the End of the Dosing Interval (Ctrough) of Berotralstat Measure: Maximum Observed Plasma Concentration (Cmax) of Berotralstat Measure: Time of Last Measurable Plasma Concentration (Tlast) of Berotralstat Measure: Time to Maximum Plasma Concentration (Tmax) of Berotralstat.

Check registry source